Urogen Pharma Ltd.

Health Care
Biotechnology: Pharmaceutical Preparations
www.urogen.com

Moat Score
Safety Score

Market Cap $387.05M
PE -3
Debt $121.71M
Cash $124.92M
EV $383.84M
FCF -$96.38M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$115.38M
EBIT	-$83.73M
ROE	-452%
ROA	-28%
FCF	-$96.38M
Equity	$25.52M
Growth Stability	1
PE	-3.35
PB	15.17
P/FCF	-4.02
P/S	4.33
Price/Cash	0.32
Debt/Equity	4.77
Debt/FCF	-1.26
Net Margins	-136%
Gross Margins	90%
Op. Margins	-94%
Sales Growth YoY	21%
Sales Growth QoQ	15%
Sales CAGR	101%
Equity CAGR	-1%
Earnings Growth YoY	8%

Earnings Growth QoQ	-29%
Sales CAGR 5Y	239%
Equity CAGR 5Y	-9%
Earnings CAGR 3Y	24%
Sales CAGR 3Y	24%
Market Cap	$387.05M
Revenue	$89.36M
Assets	$301.94M
Total Debt	$121.71M
Cash	$124.92M
Shares Outstanding	37.8M
EV	383.84M
Moat Score	1%
Safety Score	51%
Working Capital	262.31M
Current Ratio	9
Gross Profit	$80.67M
Shares Growth 3y	22%
Equity Growth QoQ	-16%
Equity Growth YoY	-161%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Its lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy.

SEC Filings

Direct access to Urogen Pharma Ltd. (URGN) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Urogen Pharma Ltd. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Urogen Pharma Ltd. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Urogen Pharma Ltd. Discounted Cash Flow

Fully customizable DCF calculator online for Urogen Pharma Ltd..

Years

Calculation mode

= -$964M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$96M	-$96M	-$96M	-$96M	-$96M	-$96M	-$96M	-$96M	-$96M	-$96M	-$96M	-$964M
DCF		-$88M	-$80M	-$72M	-$66M	-$60M	-$54M	-$49M	-$45M	-$41M	-$37M	-$372M
Value	-$964M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-	-25%	-255%	-7K%	-584K%	-1K%	-231%	-171%	-124%	-136%
ROA	-	-	-26%	-73%	-52%	-103%	-77%	-58%	-37%	-28%
ROE	-	-	-30%	-84%	-58%	-133%	-1K%	123%	157%	-452%

Bad Net Margins (-135.74%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-	-	-	-0	-1.11	-1.29	-1.26
Debt over Equity	-	-	-	-	-	-	0	-1.09	-1.51	4.77
Growth Stability	-	-	-	-	-	-	-	-	-	1

Good Debt/FCF ratio (-1.26)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Bad Debt/Equity ratio (4.77)

The company is overleveraged and has a bad balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-	-53%	-86%	-98%	65K%	307%	34%	29%	239%
Earnings YoY growth	-	-67%	372%	263%	39%	22%	-14%	-1%	-7%	-
Equity YoY growth	-	0%	320%	31%	100%	-47%	-91%	-1K%	-27%	-9%
FCF YoY growth	-	-147%	-382%	285%	88%	50%	-20%	3%	-13%	-